Vote of Confidence, page-21

Pleased to see an update through Dr Kelly's blog today.

I'm not fazed by modest delays. I appreciate the complexities and potential for delays in arranging trials. But I do expect to be promptly informed as to the reason for any delay, and the current state of play. That tells me that the company is continuing to be accountable and honest with its shareholders, and that it's still focused on delivering shareholder value - conserving capital, minimising costs, expediting progress towards results etc. That's the reason I invested in the first place, and why this company has so significantly outperformed NRT, in my view.

It's therefore pleasing to see the short but informative blog posting from Dr Kelly, which explains the delay and exactly where the trial arrangements are up to. Ideally I would have liked to have seen a revised estimate (date range) for commencement of the first trial, but I'm happy enough with what he's provided.